[{"NetIncomeLoss_1_Q2_USD":-21967000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":36708188.0,"CommitmentsAndContingencies_0_Q2_USD":null,"LiabilitiesNoncurrent_0_Q2_USD":1184000.0,"GainLossOnSaleOfPropertyPlantEquipment_2_Q2_USD":-29000.0,"RestrictedCashCurrent_0_Q2_USD":147000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-42000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":52900000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-82959000.0,"Depreciation_2_Q2_USD":485000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":36675876.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1188047.0,"InterestIncomeExpenseNonoperatingNet_1_Q2_USD":34000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":42000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_2_Q2_USD":0.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":512000.0,"AssetsCurrent_0_Q2_USD":260233000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":161000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":497000.0,"UnrecognizedTaxBenefits_0_Q2_USD":0.0,"CommonStockSharesIssued_0_Q2_shares":36722669.0,"InterestIncomeExpenseNonoperatingNet_2_Q2_USD":40000.0,"Assets_0_Q2_USD":264450000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":7934000.0,"OperatingLeaseLiability_0_Q2_USD":1275000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":24008000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":14095000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":2289000.0,"ProceedsFromStockPlans_2_Q2_USD":175000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":56000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":28000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"CommonStockValue_0_Q2_USD":4000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":14848000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-3155000.0,"PaymentsOfStockIssuanceCosts_2_Q2_USD":2000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-38718000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-21925000.0,"AccruedEmployeeBenefitsCurrent_0_Q2_USD":2348000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":169070000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":683000.0,"Liabilities_0_Q2_USD":9381000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-42000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-42000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":705000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":625000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-42000.0,"ShareBasedCompensation_2_Q2_USD":7150000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-118221000.0,"DeferredFinanceCostsCurrentNet_0_Q2_USD":117000.0,"CommonStockSharesOutstanding_0_Q2_shares":36722669.0,"RestrictedCashNoncurrent_0_Q2_USD":75000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":82235000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":4452000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-35967000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":483000.0,"LiabilitiesCurrent_0_Q2_USD":8197000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-149038000.0,"AccountsPayableCurrent_0_Q2_USD":963000.0,"NonoperatingIncomeExpense_1_Q2_USD":62000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":8612000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":532000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":15000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0574,"AdditionalPaidInCapital_0_Q2_USD":404145000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":169292000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":2884000.0,"NetIncomeLoss_2_Q2_USD":-38760000.0,"NonoperatingIncomeExpense_2_Q2_USD":96000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-42000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":82198000.0,"StockholdersEquity_0_Q2_USD":255069000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1258000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"InterestReceivableCurrent_0_Q2_USD":131000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":174000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":172000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":2301000.0,"CommonStockSharesAuthorized_0_Q2_shares":300000000.0,"OperatingIncomeLoss_2_Q2_USD":-38856000.0,"OperatingIncomeLoss_1_Q2_USD":-22029000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":724000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":82156000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":7150000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":4452000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":592000.0,"OperatingExpenses_2_Q2_USD":38856000.0,"OperatingExpenses_1_Q2_USD":22029000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.06,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.6,"ProfitLoss_2_Q2_USD":-38760000.0,"OtherLiabilitiesCurrent_0_Q2_USD":586000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":264450000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":505000.0,"Ticker":"STOK","CIK":"1623526","name":"STOKE THERAPEUTICS, INC.","OfficialName":"Stoke Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"702726891.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210810"}]